Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.
/wp-content/uploads/2018/04/logo.jpg00Jean-François Mayol/wp-content/uploads/2018/04/logo.jpgJean-François Mayol2019-07-15 13:00:152020-03-24 09:23:59Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Geneva, Switzerland – 02 May 2019 – AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,with Boehringer […]
/wp-content/uploads/2018/04/logo.jpg00Jean-François Mayol/wp-content/uploads/2018/04/logo.jpgJean-François Mayol2019-05-02 09:00:122019-05-02 08:24:39AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091
Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens), its […]
Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF
/wp-content/uploads/2018/04/logo.jpg00Aurelie Kowalski/wp-content/uploads/2018/04/logo.jpgAurelie Kowalski2019-04-24 07:44:092019-04-24 07:51:15AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine
Geneva, Switzerland – 12 November 2018 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF […]
/wp-content/uploads/2018/04/logo.jpg00Jean-François Mayol/wp-content/uploads/2018/04/logo.jpgJean-François Mayol2018-11-12 09:00:302019-01-07 20:58:03AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round
Geneva, Switzerland – 19 September 2018 – We are pleased to announce that AMAL Therapeutics is featured in the September edition of BioPharma Dealmakers (Nature Research), outlining the promise of protein-based therapeutics cancer vaccine in oncology. View PDF
/wp-content/uploads/2018/04/logo.jpg00Jean-François Mayol/wp-content/uploads/2018/04/logo.jpgJean-François Mayol2018-09-18 15:06:482018-09-25 15:41:02Amal Therapeutics featured in September edition of BioPharma Dealmaker (Springer-Nature)
Geneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). View PDF
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2017-09-05 13:20:492018-03-14 16:02:28AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round
Each year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2016-09-14 13:57:332018-03-14 16:02:30TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10
Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
/wp-content/uploads/2018/04/logo.jpg00canvax/wp-content/uploads/2018/04/logo.jpgcanvax2016-08-25 13:57:302018-03-14 16:02:24Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary
Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
/in News /by Jean-François MayolBoehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.
AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim to evaluate ATP128 in combination with BI754091
/in News /by Jean-François MayolGeneva, Switzerland – 02 May 2019 – AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has entered into a collaborative agreement with Boehringer Ingelheim. AMAL will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128,with Boehringer […]
Amal Therapeutics to publish R&D outcomes in JCI Insight
/in News /by Jean-François MayolGeneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens), its […]
AMAL Therapeutics and Natera to Partner on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine
/in News /by Aurelie KowalskiNatera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF
AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round
/in News /by Jean-François MayolGeneva, Switzerland – 12 November 2018 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF […]
Amal Therapeutics featured in September edition of BioPharma Dealmaker (Springer-Nature)
/in News /by Jean-François MayolGeneva, Switzerland – 19 September 2018 – We are pleased to announce that AMAL Therapeutics is featured in the September edition of BioPharma Dealmakers (Nature Research), outlining the promise of protein-based therapeutics cancer vaccine in oncology. View PDF
AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round
/in News /by canvaxGeneva, Switzerland – 5 September 2017 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). View PDF
TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10
/in News /by canvaxEach year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary
/in News /by canvaxAmongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
Amal Therapeutics to publish R&D outcomes in Molecular Therapy
/in News /by canvaxGeneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF